BioMerieux Research and Development Expenses 2017-2024 | BMXMF

BioMerieux research and development expenses for the twelve months ending December 31, 2024 were $0M, a 0% increase year-over-year.

  • BioMerieux annual research and development expenses for 2024 were $0.532B, a 6.8% increase from 2023.
  • BioMerieux annual research and development expenses for 2023 were $0.498B, a 5.83% increase from 2022.
  • BioMerieux annual research and development expenses for 2022 were $0.471B, a 2.24% increase from 2021.

BioMerieux Research and Development Expenses 2017-2024 | BMXMF

  • BioMerieux annual research and development expenses for 2024 were $0.532B, a 6.8% increase from 2023.
  • BioMerieux annual research and development expenses for 2023 were $0.498B, a 5.83% increase from 2022.
  • BioMerieux annual research and development expenses for 2022 were $0.471B, a 2.24% increase from 2021.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$136B
CVS Health (CVS)$78.4B
Elevance Health (ELV)$62.6B
Cencora (COR)$56.8B
DiDi Global (DIDIY)$26.9B
Labcorp Holdings (LH)$20.4B
Natera (NTRA)$19B
EUROFINS SCIENT (ERFSF)$14B
CochLear (CHEOY)$13.1B
Solventum (SOLV)$12.7B
ICON (ICLR)$11.6B
Revvity (RVTY)$11B
Viatris (VTRS)$10.4B
Avantor (AVTR)$9.1B
Medpace Holdings (MEDP)$9B
Sonic Healthcare (SKHHY)$8.9B
HealthEquity (HQY)$8.4B
Caris Life Sciences,�Inc (CAI)$7.7B
Charles River Laboratories (CRL)$7.6B
Amplifon S.p.A (AMFPF)$5.4B
Bausch + Lomb (BLCO)$4.9B
BrightSpring Health Services (BTSG)$3.5B
Sotera Health (SHC)$3.1B
Surgery Partners (SGRY)$2.9B
Concentras Parent (CON)$2.5B
Organon (OGN)$2.5B
Alignment Healthcare (ALHC)$2.5B
GeneDx Holdings (WGS)$2.2B
Progyny (PGNY)$1.9B
PACS (PACS)$1.8B